Stay updated with breaking news from Urologic Oncologist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ASCO 2024, Prostate Cancer, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), Diagnostic Imaging in Prostate Cancer, Artificial Intelligence in diagnostics, Innovation and Potential for Diagnostic Imaging in Prostate Cancer, PI-RADS guidelines.
ASCO 2024, Prostate Cancer, Prostate Cancer Pathology, Artificial Intelligence and Deep Learning in Prostate Cancer Pathology, TMPRSS2:ERG fusion status.
ASCO 2024, Prostate Cancer, Artificial Intelligence to Optimize Systemic Therapy, Artificial Intelligence to Optimize Systemic Therapy for Prostate Cancer, Optimize Systemic Therapy for Prostate Cancer, artificial intelligence for prostate cancer, artificial intelligence for prostate cancer diagnostics.
ASCO 2024, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), JNJ-69086420 (JNJ-6420), Actinium-225 (225Ac), Targeting Human Kallikrein 2, JNJ-6420 adverse events.
ASCO 2024 molecular testing to guide perioperative systemic therapy for urothelial cancer, ctDNA testing, adjuvant immune checkpoint blockade, TOMBOLA trial.